Definium Therapeutics Announces Positive Phase 3 Topline Data for DT120

What Happened

• On September 14, 2026, Definium Therapeutics, Inc. announced positive topline results from its Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder (GAD). The company issued a press release and posted a presentation summarizing the topline data.

Key Details

• Date of disclosure: September 14, 2026 (8-K filed).
• Program: DT120 ODT, Phase 3 Panorama study, indication — generalized anxiety disorder.
• Materials posted: Press Release (Exhibit 99.1) and Panorama Topline Data Presentation (Exhibit 99.2) on the company website.
• SEC items: Disclosure made under Item 7.01 (Regulation FD disclosure) and Item 8.01 (Other events).

Why It Matters

• A positive Phase 3 topline readout is a major clinical milestone that validates late-stage study outcomes and informs next steps such as full data analysis and potential regulatory discussions. For investors, this announcement is material to Definium’s clinical progress and future development timeline for DT120 ODT. The press release and presentation attached to the 8-K provide the company’s official summary of the topline findings.